Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Experts: HHS Review Proposal May Free Industry From Regulatory Red Tape

Executive Summary

Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.

You may also be interested in...



Most Regs Would Get 10-Year Reviews Under HHS Proposal

The rule would mandate that agencies assess rules that affect small entities once every decade to ensure they were still appropriate.

Priority Lane: Guidances On Risky Devices, 510(k) Reform Top FDA’s To-Do List

The US FDA hopes to finalize or issue draft guidance documents on about 30 topics in fiscal year 2021.

FAQ Sheet From HHS Says FDA ‘Rarely Enforced’ Premarket Review Of LDTs

The US HHS defends its recent decision to relieve the FDA from oversight of laboratory developed tests in a new FAQ sheet, saying the agency hardly ever enforced the premarket review of LDTs in the first place.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel